8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2006 / Multicenter, double-blind, randomized controlled trial
In the GAIT trial, 1,583 patients with symptomatic knee osteoarthritis were randomized to receive 1500 mg glucosamine, 1200 mg chondroitin sulfate, both, 200 mg celecoxib, or placebo daily for 24 weeks. Overall, response rates were not significantly higher than placebo (60.1%) for glucosamine (+3.9 percentage points, P=0.30), chondroitin sulfate (+5.3 percentage points, P=0.17), or the combination (+6.5 percentage points, P=0.09), whereas celecoxib was significantly higher (+10.0 percentage points, P=0.008). In an exploratory subgroup with moderate-to-severe baseline pain, combined therapy had a significantly higher response rate than placebo (79.2% vs. 54.3%, P=0.002).
Clegg DO, Reda DJ, Harris CL, et al. N Engl J Med, 2006. PMID 16495392
2006 / Randomized controlled trial
A randomized trial of 48 adults aged 57 +/- 3 years evaluated 1-year changes in bone mineral density across caloric restriction, exercise, or a healthy lifestyle control. Caloric restriction decreased bone mineral density at the total hip (-2.2% +/- 3.1%), intertrochanter (-2.1% +/- 3.4%), and spine (-2.2% +/- 3.3%) compared to controls. Conversely, exercise-induced weight loss did not result in bone loss at any site despite comparable reductions in body weight.
Villareal DT, Fontana L, Weiss EP, et al. Arch Intern Med, 2006. PMID 17159017
2005 / Randomized crossover trial
Thirteen healthy women completed a randomized crossover study comparing 10 days of a moderate-protein diet (1.0 g/kg) to a high-protein diet (2.1 g/kg) following a 2-week lead-in diet. Intestinal calcium absorption increased on the high-protein diet compared to the moderate-protein diet (26.2 +/- 1.9% vs. 18.5 +/- 1.6%, P < 0.0001), as did urinary calcium (5.23 +/- 0.37 vs. 3.57 +/- 0.35 mmol/d, P < 0.0001). The high-protein diet significantly reduced the fraction of urinary calcium of bone origin, showed a nonsignificant trend toward lower bone turnover, and had no effect on net bone balance.
Kerstetter JE, O'Brien KO, Caseria DM, et al. J Clin Endocrinol Metab, 2005. PMID 15546911
2005 / Randomized controlled trial
Eighty obese patients with knee osteoarthritis were randomized to an intensive low-energy diet (3.4 MJ/day) with weekly counseling or a control diet (5 MJ/day) with written guidance. The low-energy group lost 11.1% of body weight compared to 4.3% in controls (difference 6.8%, 95% CI: 5.5 to 8.1%, P < 0.0001). Total WOMAC scores improved in the low-energy cohort (mean difference -219.3 mm, P = 0.005), and every 1% reduction in body fat predicted a 9.4% improvement in symptoms.
Christensen R, Astrup A, Bliddal H Osteoarthritis Cartilage, 2005. PMID 15639633
2005 / Randomized controlled trial
In a randomized trial of 354 females enrolled at pubertal stage 2, participants received approximately 670 mg/day of supplemental calcium or placebo over up to 7 years. Supplementation significantly increased all measured bone mineral density endpoints at year 4. By year 7, the benefit vanished for total-body and distal radius bone mineral density, though significant effects remained at metacarpal sites.
Matkovic V, Goel PK, Badenhop-Stevens NE, et al. Am J Clin Nutr, 2005. PMID 15640478
2005 / Randomized, double-blind, placebo-controlled trial
In a randomized, double-blind, placebo-controlled trial, 300 patients with knee osteoarthritis were assigned to receive 800 mg chondroitin sulfate (CS) or placebo once daily for 2 years. Patients receiving placebo experienced a mean joint space loss of 0.14 +/- 0.61 mm after 2 years (P = 0.001 compared with baseline), whereas patients receiving CS showed no change (0.00 +/- 0.53 mm; P not significant compared with baseline). The difference in joint space loss between the two groups was significant for mean joint space width (0.14 +/- 0.57 mm; P = 0.04) and minimum joint space width (0.12 +/- 0.52 mm; P = 0.05). There was no significant symptomatic effect on pain or function, and CS was well tolerated.
Michel BA, Stucki G, Frey D, et al. Arthritis Rheum, 2005. PMID 15751094
2005 / Randomized controlled trial
A randomized controlled trial evaluated pubertal adolescents given 8 g daily of mixed inulin-type fructans or maltodextrin placebo. Calcium absorption was significantly higher with fructans at eight weeks (difference 8.5%, P < 0.001) and one year (difference 5.9%, P = 0.04). After one year, the fructan group gained significantly more whole-body bone mineral content (difference 35 g, P = 0.03) and bone mineral density (difference 0.015 g/cm2, P = 0.01).
Abrams SA, Griffin IJ, Hawthorne KM, et al. Am J Clin Nutr, 2005. PMID 16087995
2005 / Three-way crossover trial
Twenty young women participated in a crossover trial evaluating fractional calcium absorption from 250 mg of calcium supplied as cow's milk or fortified soymilks. Absorption from calcium carbonate-fortified soymilk (0.211 +/- 0.057) did not differ significantly from cow's milk (0.217 +/- 0.040). Both provided significantly higher calcium absorption than tricalcium phosphate-fortified soymilk (0.181 +/- 0.039, P < 0.05).
Zhao Y, Martin BR, Weaver CM J Nutr, 2005. PMID 16177199
2004 / Randomized controlled trial
In an 89-woman randomized trial lasting two years, researchers examined the effects of soymilk with isoflavones, transdermal progesterone, or both on bone mineral density. Lumbar spine bone mineral density changes did not differ from zero with isoflavone soymilk (+1.1%) or progesterone alone (-1.1%), but controls lost -4.2% and combined treatment lost -2.8%. Femoral neck bone mineral density did not change significantly in any group.
Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, et al. Eur J Nutr, 2004. PMID 15309425
2004 / Randomized controlled trial
One hundred thirty-five adults with osteoarthritis or chronic knee pain were randomized to consume 40 g of soy protein or milk-based protein daily for 3 months. Soy protein improved range of motion, pain, and quality of life compared to milk protein, but these benefits were driven by effects in men. In men, soy protein significantly raised serum IGF-I and reduced YKL-40 levels.
Arjmandi BH, Khalil DA, Lucas EA, et al. Phytomedicine, 2004. PMID 15636169
2003 / Double-blind, randomized, parallel-group trial
Postmenopausal women were randomly assigned to consume 40 g daily of either soy protein (SP) or milk-based protein (MBP) for 3 months. Both supplements increased serum IGF-I, but SP had a more pronounced effect than MBP, with the greatest impact (a 97% increase) seen in women not on HRT. Urinary Dpd excretion was significantly reduced by SP, but not MBP, driven by changes in women not on HRT. In addition, MBP led to a 33% increase in urinary calcium excretion, whereas SP did not.
Arjmandi BH, Khalil DA, Smith BJ, et al. J Clin Endocrinol Metab, 2003. PMID 12629084
2002 / Randomized controlled trial
Fifty-eight postmenopausal women not receiving hormone replacement therapy were randomly allocated to eat either 100 g of dried plums or 75 g of dried apples each day for three months. Only dried plum intake led to significant rises in serum insulin-like growth factor-I and bone-specific alkaline phosphatase activity compared with baseline. Neither dietary regimen produced changes in serum or urinary markers of bone resorption.
Arjmandi BH, Khalil DA, Lucas EA, et al. J Womens Health Gend Based Med, 2002. PMID 11860726
2002 / Randomized controlled trial
A randomized controlled trial assigned 90 healthy postmenopausal women to receive hormone replacement therapy, 54 mg/day of genistein, or placebo for one year. At 12 months, genistein increased femoral neck bone mineral density by 3.6 +/- 3% and lumbar spine density by 3 +/- 2% (P < 0.001 compared to placebo). Genistein also decreased urinary pyridinium cross-links and increased bone-specific alkaline phosphatase and osteocalcin.
Morabito N, Crisafulli A, Vergara C, et al. J Bone Miner Res, 2002. PMID 12369794
2002 / 3-year randomized, placebo-controlled, double-blind study
A randomized, double-blind trial assigned 202 patients with knee osteoarthritis to receive oral glucosamine sulfate (1500 mg once daily) or placebo for 3 years. After 3 years, progressive joint space narrowing was -0.19 mm (95% CI, -0.29 to -0.09 mm) with placebo, compared to no average change with glucosamine sulfate (0.04 mm; 95% CI, -0.06 to 0.14 mm; P = .001). Predefined severe narrowings (>0.5 mm) occurred in 5% of glucosamine sulfate patients compared to 14% of placebo patients (P = .05). Glucosamine sulfate also led to a 20% to 25% improvement in symptoms, showing significant final differences on the Lequesne index and WOMAC total index and subscales.
Pavelká K, Gatterová J, Olejarová M, et al. Arch Intern Med, 2002. PMID 12374520
2001 / Randomized controlled trial
A 6-month randomized trial evaluated 27 obese postmenopausal women assigned to moderate energy restriction or weight maintenance. In the weight-loss group, body weight decreased by 10.2 +/- 5.5% and total-body bone mineral density fell by 1.2 +/- 1.2%, differing significantly from controls (P < 0.05). Energy-restricted women also demonstrated chronically elevated markers of bone resorption and formation compared to weight maintainers (P < 0.05).
Ricci TA, Heymsfield SB, Pierson RN, et al. Am J Clin Nutr, 2001. PMID 11157334
2001 / Randomised, double-blind, placebo-controlled trial
In a 3-year randomized trial, 212 patients with knee osteoarthritis received either 1500 mg oral glucosamine sulphate or placebo once daily. Patients on placebo experienced progressive joint-space narrowing with a mean joint-space loss of -0.31 mm (95% CI -0.48 to -0.13), whereas patients taking glucosamine sulphate had no significant loss (-0.06 mm, 95% CI -0.22 to 0.09). WOMAC scores showed symptoms worsened slightly on placebo but improved with glucosamine sulphate, with no differences in safety or reasons for early withdrawal between groups.
Reginster JY, Deroisy R, Rovati LC, et al. Lancet, 2001. PMID 11214126
2001 / Randomized controlled trial
A 6-week randomized trial assigned 261 patients with knee osteoarthritis to receive a standardized ginger extract or placebo twice daily. Among 247 evaluable patients, 63% in the ginger group versus 50% in the placebo group achieved at least a 15 mm pain reduction on standing (p = 0.048). Mean reduction in standing pain was 24.5 mm versus 16.4 mm (p = 0.005), though mild gastrointestinal adverse events were more frequent with ginger (59 versus 21 patients).
Altman RD, Marcussen KC Arthritis Rheum, 2001. PMID 11710709
2000 / Randomized crossover trial
Patients with hip or knee osteoarthritis participated in a randomized, double-blind crossover study testing three-week periods of ginger extract, ibuprofen, and placebo. Overall rankings favored ibuprofen, followed by ginger, and then placebo for pain and the Lequesne index. Across the complete crossover analysis, ginger did not differ significantly from placebo, although exploratory testing showed an effect during the initial treatment block.
Bliddal H, Rosetzsky A, Schlichting P, et al. Osteoarthritis Cartilage, 2000. PMID 10607493
2000 / Non-randomized controlled trial (5-year follow-up)
Eighteen postmenopausal women who previously completed a 9-month intervention volunteered for a 5-year follow-up trial. Nine engaged in weighted vest plus jumping exercise three times per week for 32 weeks per year over 5 years, while nine controls remained active without the program. After 5 years, changes in BMD for exercisers were +1.54% +/- 2.37%, -0.24% +/- 1.02%, and -0.82% +/- 1.04% at the femoral neck, trochanter, and total hip, respectively, compared to decreases of -4.43% +/- 0.93%, -3.43% +/- 1.09%, and -3.80% +/- 1.03% in controls.
Snow CM, Shaw JM, Winters KM, et al. J Gerontol A Biol Sci Med Sci, 2000. PMID 10995045
1998 / Clinical trial protocol
The Women's Health Initiative protocol enrolled postmenopausal women aged 50 to 79 across 40 clinical centers, with an average follow-up of about 9 years. The randomized clinical trial planned to evaluate a low-fat eating pattern, hormone replacement therapy, and calcium plus vitamin D supplementation in roughly 64,500 women. An observational component enrolled approximately 100,000 additional women to assess common causes of morbidity and mortality.
Authors not listed Control Clin Trials, 1998. PMID 9492970
1997 / Randomized crossover trial
Nine female volunteers received 400 mg calcium from Emmental cheese, milk, sesame seeds, spinach, calcium salt, or a control meal in random order. Serum ionized calcium increased significantly after cheese (P = 0.004) or calcium salt (P = 0.05), while intact parathyroid hormone significantly declined after cheese (P = 0.002) and calcium salt (P = 0.007) versus control. Urinary calcium excretion was higher than control with cheese (141%, P = 0.001), milk (107%, P = 0.004), and calcium salt (75%, P = 0.02). Calcium from sesame seeds and spinach did not cause an acute response in calcium metabolism.
Kärkkäinen MU, Wiersma JW, Lamberg-Allardt CJ Am J Clin Nutr, 1997. PMID 9174467
1994 / Controlled, single-blind clinical trial psychological analysis
Researchers examined psychological parameters among 53 rheumatoid arthritis patients participating in a trial of fasting and vegetarian diet compared with 71 non-participating RA patients. Participants had higher internal and lower chance scores on the MHLCS, lower belief in ordinary medicine, and higher belief in alternative treatments. Among patients randomized to the vegetarian diet, responders did not differ from non-responders on MHLCS scores, but responders had significantly lower belief in ordinary medical treatment. General Health Questionnaire scores favoured vegetarians over omnivores and responders over non-responders, indicating dietary treatment decreased psychological distress.
Kjeldsen-Kragh J, Haugen M, Førre O, et al. Br J Rheumatol, 1994. PMID 8205407
1993 / Randomized clinical trial
A randomized clinical trial compared arthroscopic subacromial decompression, a 3- to 6-month supervised exercise regimen, and 12 sessions of placebo soft laser treatment in 125 patients with stage II impingement syndrome. After six months, both active treatments improved the condition significantly compared with placebo, but the difference in improvement in overall Neer score between surgery and exercises was not significant (4.0 [95% CI -2 to 11]; 2.0 [-1.4 to 5.4] adjusted for sex). No differences were found in duration of sick leave or daily analgesic intake, while treatment costs were higher for surgery (£720 vs £390).
Brox JI, Staff PH, Ljunggren AE, et al. BMJ, 1993. PMID 8241852
1992 / Randomized controlled trial
In an 18-month randomized trial, 3,270 ambulatory women (mean age 84 years) received daily supplementation with 1.2 g elemental calcium plus 800 IU vitamin D3 or a double placebo. Calcium and vitamin D3 reduced hip fractures by 43 percent (P = 0.043) and total nonvertebral fractures by 32 percent (P = 0.015). Proximal femur bone density rose 2.7 percent with active treatment and decreased 4.6 percent in the placebo group (P < 0.001).
Chapuy MC, Arlot ME, Duboeuf F, et al. N Engl J Med, 1992. PMID 1331788